Skip to main content
. 2020 Jul 29;20:350. doi: 10.1186/s12935-020-01402-9

Fig. 5.

Fig. 5

FOXD3-AS1 knockdown enhanced cisplatin sensitivity of A549/DDP cells in vivo. a Growth curve of xenograft tumors after different treatments. b Weights of dissected tumors in different groups. c qRT-PCR determination of FOXD3-AS1 expression in dissected tumor tissues in different groups. N = 6 biological samples, and each sample for FOXD3-AS1 expression was assayed in triplicates. Significant differences between groups were shown as *P < 0.05